

• **London**

One Northumberland Avenue
Trafalgar Square
London WC2N 5BW

• **Hong Kong**

Suites 2207-2209
Tower Two, Lippo Centre
89 Queensway, Admiralty
Hong Kong

Media Release

**FOR
IMMEDIATE
RELEASE**

Contact

Christos S. Efessiou
Phone: 202-965-2288

Email :
cefessiou@RxBioSci.com

Washington, DC - May 8, 2007 [Strategic BioSciences](http://www.StrategicBioSciences.com) a specialty pharmaceutical company, is pleased to announce that it has secured the global exclusive rights to MucoAd™, a mucoadhesive pharmaceutical agent that can be “loaded” with nearly any pharmaceutical preparation and delivered to a variety of mucosal tissues.

MucoAd™ is a patented non-toxic, non-irritating, liquid polymer mucoadhesive carrier that prolongs the contact time between drug and mucosa, thus increasing bioavailability and efficacy of the delivered drug. The adherence of pharmaceuticals to the mucosa may permit lower doses of the administered drug so that the desired therapeutic affect could be achieved with fewer adverse reactions.

The MucoAd™ technology is versatile. It can be applied to powders, gels, microspheres, liposomes, and liquid formulations. It is currently being tested for intranasal applications, and other sites of application include sublingual, ophthalmic, vaginal, and rectal. Potential transmucosal derivatives in discussion include nasal decongestants, second-generation antihistamines, second-generation H₁-antagonists, topical corticosteroids, CNS drugs, anti-emetics, anti-infectives, cold & cough preparations, asthma medications, vascular products, periodontal products, , and topical agents for the treatment of slow-healing wounds.

The company is now developing the methods and technology to assess and adjust the required mucoadhesive properties for several specific medications. Thus far, researchers have shown that using MucoAd™ with a decongestant preparation of xylometazoline 0.1% increased clinical efficacy as compared to the standard decongestant spray while also decreasing rebound swelling and other side effects. MucoAd™ is also being used to develop a stable intranasal solution of the antihistamine loratadine, commonly known as Claritin® or Alavert®, which formerly was practically insoluble. A topical nasal formulation of the anti-emetic agent clopramide is also in development.

Christos S. Efessiou, Strategic BioSciences Chief Executive Officer, commented “MucoAd™ represents the New Frontier in drug delivery because it enables the administration of a nearly limitless number of pharmaceutical products via a safe and effective route. More importantly, as MucoAd™ bypasses the digestive tract and liver, it slows deactivation and reduces common irritating GI side effects associated with many oral medications. We are excited at the possibilities MucoAd™ offers in the administration of medications which up to now could only be delivered by injection such as insulin and epinephrine.”

Neil White, Director of Fortune Apex Development said “Strategic BioSciences represents a significant step towards developing the applications, for our unique, patented technology, which in addition to clinical advantages, offers MucoAd™ licensees significant opportunities for patent extensions.”

Strategic Pharmaceuticals Company, doing business as [Strategic BioSciences](http://www.StrategicBioSciences.com), is a District of Columbia based pharmaceutical company. It is the joint venture of SRxA Holdings Inc, an affiliate of [Strategic Pharmaceutical Advisors](http://www.StrategicPharmaceuticalAdvisors.com) of Washington, DC and [Fortune Apex Development](http://www.FortuneApexDevelopment.com) of Hong Kong, The licensing agreement granting Strategic BioSciences the exclusive global rights to MucoAd™, was recently signed in Seoul, Korea.